Fig. 2

Association between EMP3 and clinicopathological characteristics of gliomas (A). The landscape of EMP3- related clinicopathological features of gliomas in the Chinese Glioma Genome Atlas (CGGA) database (B). The landscape of EMP3- related clinicopathological features of gliomas in The Cancer Genome Atlas (TCGA) database (C) and (G). EMP3 was significantly increased in the O6- methylguanine- DNA methyltransferase (MGMT) promoter–unmethylated gliomas in the CGGA and TCGA databases. The significance of the difference was tested using an unpaired t test (D) and (H). EMP3 was significantly increased in gliomas without 1p19q codeletion in the CGGA and TCGA databases. The significance of the difference was tested with an unpaired t test (E) and (I). EMP3 has significantly increased in gliomas without isocitrate dehydrogenase (IDH) mutation in the CGGA and TCGA databases. The significance of the difference was tested with an unpaired t test (F) and (J). EMP3 was significantly increased in higher-grade gliomas in the CGGA and TCGA databases. One-way ANOVA tested the significance of the difference